Chemokine Therapeutics Announces Issuance of U.S. Patent
Posted on: Wednesday, 2 July 2008, 09:00 CDT
Chemokine Therapeutics Corp. (the "Company") (TSX: CTI)(OTCBB: CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases, today announced that it has been granted U.S. Patent No. 7,378,098.
Patent No. 7,378,098 entitled "CXC Chemokine Receptor 4 Agonist Peptides" is related to treatment of patients in need of bone marrow or stem cell transplantation. This patent is based on evidence that treatment with SDF-1 chemokine analog prevents reduction of normal bone marrow stem cells and restores white blood cells, which reduce susceptibility to infections in cancer patients following chemotherapy treatment.
"This patent strengthens the foundation for our work with our drug candidate CTCE-0214, for hematogical support; mobilization of stem cells and white blood cells into circulation, which is currently in Phase I development," said Dr. Donald Wong, Vice President, Drug Development.
About Chemokine Therapeutics Corp. (TSX: CTI)(OTCBB: CHKT)
Chemokine Therapeutics is a product-focused biotechnology company developing drug candidates in the field of chemokines. Chemokines are a class of signaling proteins that play a critical role in the growth, differentiation, and maturation of cells necessary for fighting infection as well as tissue repair and regeneration. Chemokines also have an important role in cancer metastasis and growth. Chemokine Therapeutics is a leader in research in the field of chemokines and has several products in various stages of development.
Contacts: Chemokine Therapeutics Corp. Mr. Don Evans Vice President, Corporate Communications (604) 738-6644 ext. 22 or Toll Free: 1-888-822-0305 ext. 22 (604) 738-6645 (FAX) Email: devans@chemokine.net Website: www.chemokine.net
SOURCE: Chemokine Therapeutics Corp.
Source: MARKET WIRE
Related Articles
- Chemokine Therapeutics Announces Breast Cancer Data Presented at a Metastasis Conference With Lead Compound, CTCE-9908
- Chemokine Therapeutics Announces Issuance of Two New U.S. Patents
- Chemokine Therapeutics Announces Liver Cancer Data Presented at the AACR Meeting on Its Lead Compound, CTCE-9908
- Chemokine Therapeutics Receives Approval From Health Canada to Commence Phase II Study in Liver Cancer
- Chemokine Therapeutics Corp.: Two Additional Abstracts Accepted for Presentation at the Upcoming Molecular Targets and Cancer Therapeutics International Conference
- Chemokine Therapeutics Announces Preliminary Results of CTCE-9908 Phase Ib/II Clinical Trial in Late Stage Cancer Patients
- Chemokine Therapeutic to Be Studied By Cancer Center
- Chemokine Therapeutics to Present New Data on Its Lead Anti Cancer Drug at the 2006 Conference on Angiogenesis in Miami
- Chemokine Therapeutics to Present Phase 1 Clinical Data at the 2006 Blood and Bone Marrow Transplantation Conference
 |
 |
User Comments (0)
RSS Feeds